# Cellular Immunotherapy in Recipients of HLA-matched, Living Donor Kidney Transplants

> **NCT03363945** · PHASE3 · COMPLETED · sponsor: **Medeor Therapeutics, Inc.** · enrollment: 30 (actual)

## Conditions studied

- Kidney Transplant Rejection

## Interventions

- **BIOLOGICAL:** MDR-101

## Key facts

- **NCT ID:** NCT03363945
- **Lead sponsor:** Medeor Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-03-15
- **Primary completion:** 2024-04-11
- **Final completion:** 2024-04-11
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2024-06-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03363945

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03363945, "Cellular Immunotherapy in Recipients of HLA-matched, Living Donor Kidney Transplants". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03363945. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*